All News
$2 Million in Research Grants for Juvenile Arthritis
July is Juvenile Arthritis Awareness Month, and while many people think of arthritis as a disease of aging, nearly 300,000 children in the U.S. are living with a rheumatic disease.
Read Article
Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read Article
ACP Position Paper on Dietary Supplements
More than half of U.S. adults use dietary supplements, yet only a quarter use supplements recommended by a healthcare professional, and current law lets supplements reach the market with no premarket safety evaluation, unlike drugs or food additives.
Read Article
CAR-T Therapy: EULAR 2026 Conference Recap
CAR-T therapy in autoimmune disease is moving fast - but is it ready to move beyond specialized referral centers? This EULAR 2026 recap covers the mechanistic data, relapse biology, and access innovations shaping that answer.
Read Article
Interferon-α as an Immunologic Driver of Sjögren's Disease
Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/Clj9u5COzQ
Dr. John Cush RheumNow ( View Tweet)
Yesterday the EMA approved upadacitinib (Rinvoq) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo - the 1st therapy approved for the most common form of vitiligo. Based on positive results from the Phase 3 Viti-Up trials https://t.co/MMv5LjZclQ https://t.co/zN41GC5T15
Dr. John Cush RheumNow ( View Tweet)
Interferon-α as an Immunologic Driver of Sjögren's Disease
Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/0BDDvR5cUB
Dr. John Cush RheumNow ( View Tweet)
Primary biliary cholangitis is a chronic cholestatic disease characterized by autoimmune-mediated destruction of bile ducts, leading to fibrosis, cirrhosis, & liver failure. Ursodeoxycholic acid is 1st line Rx. New Rx include elafibranor & seladelpar (activates peroxisome https://t.co/tKloXvJYek
Dr. John Cush RheumNow ( View Tweet)
GI dz & malnutrition in scleroderma (SSc) is common, assessed by BMI. Among 450 SSc (F/U 5.3 yrs), lower BMI were significantly assoc w/ pseudoobstruction, smaller oral aperture, higher Medsger vascular severity scores. Defines those at risk https://t.co/JY9YFOWE5C https://t.co/xFZ0rCXjQv
Dr. John Cush RheumNow ( View Tweet)
Among 784,091 pts in a UK acute MI registry, 715 (0.1%) had SLE. SLE pts were younger & more female. SLE w/ MI had signif higher adjusted all-cause mortality from 30 days (HR 1.62) to 5 years (HR 1.84), despite age & having less traditional cardiovascular comorbidities https://t.co/78oHVWTdTJ
Dr. John Cush RheumNow ( View Tweet)
Chinese cohort of 209 AOSD pts identifed 49 (23%) w/ lung dz (by CXR), yet 69% were asymptomatic. Significcant risk factors for AOSD-LD were pleuritis, MAS (HR 2.62), & Dz relapse (HR 2.6). Imaging patterns: acute exudative pattern most prevalent, followed by interstitial and https://t.co/2IPJWRJicP
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 51 studies shows vaccination is suboptimal in Rheum. Influenza Vax rates: RA 50%, SLE 42%, AS 43% & Psa 53%. Pneumococcal vaccinations even lower: 37%, 30%, 39% and 41%. More by with age & comorbidites and by rheumatologists (vs PCPs) https://t.co/3DborC9BLW https://t.co/MPDeJUH0HI
Dr. John Cush RheumNow ( View Tweet)
Systemic sclerosis metanalysis of 31 studies (32,134 pts) shows malignancy risk signif increased (SIR 1.66; CI 1.32 - 2.08). Highest: esophageal, liver, cervical, lung, & Heme (SIR 3.35 - 13.95). 7.4 yr mean from SSc to CA dx. https://t.co/IhxvfkMqkf https://t.co/dTFjD4iqth
Links:
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 31 studies (14,548 pts) looked at infection in idiopathic inflamm myopathy (IIMs). Infection prevalence was 24%, primarily Respiratory tract. PJP, aspergillosis, H zoster most prevalent pathogens. Risk factors: older age, male, DM, HTN,MDA5+ (OR 3.41), rapidly https://t.co/Go51MUOQlG
Dr. John Cush RheumNow ( View Tweet)
EMD Serono Announces FDA Breakthrough Therapy Designation for Enpatoran (TLR 7/8 inhibitors) for use in Cutaneous Lupus; based on the results from the Phase 2 WILLOW study https://t.co/TNM4whC0Qk https://t.co/70Cibg1gkW
Dr. John Cush RheumNow ( View Tweet)
DMARD Efficacy in RA-ILD
A network meta-analysis in the Journal of Autoimmunity reviews the pharmacologic options for rheumatoid arthritis–associated interstitial lung disease (RA-ILD). RA-ILD guidelines were recently presented by ERS/EULAR, but these were mainly conditional,
Dr. John Cush RheumNow ( View Tweet)
EULAR26: Vasculitis updates: Glucorticoid use in AAV and GCA
EULAR recommends a combination of glucocorticoids with either rituximab or cyclophosphamide for remission induction in life-threatening or organ-threatening AAV, followed by gradual tapering of glucocorticoids. https://t.co/9HI9SwMSSv
Dr. John Cush RheumNow ( View Tweet)
Insights into Treating Lupus - A Rheum Survey
RheumNow recently surveyed clinicians to better understand current practice patterns, educational needs, and barriers to the use of new, advanced therapies in systemic lupus erythematosus (SLE). A total of 197 clinicians completed https://t.co/HNaUK5Q9uq
Dr. John Cush RheumNow ( View Tweet)
ICYMI: B Cells at the Brink in Sjögren Disease
The current issue of Arthritis & Rheumatology reviews current understanding of the immunopathogenesis of Sjögren disease (SjD) and how that has influenced the quest for drug development for this most systemic autoimmune disorder. https://t.co/OBFqHYof5m
Dr. John Cush RheumNow ( View Tweet)
